{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:07:09Z","timestamp":1788469629480,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T00:00:00Z","timestamp":1546214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772219"],"award-info":[{"award-number":["81772219"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81420108023"],"award-info":[{"award-number":["81420108023"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"publisher","award":["2017YFD0501200"],"award-info":[{"award-number":["2017YFD0501200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"publisher","award":["2017YFD0500400"],"award-info":[{"award-number":["2017YFD0500400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003807","name":"People's Government of Jilin Province","doi-asserted-by":"publisher","award":["2015Y033"],"award-info":[{"award-number":["2015Y033"]}],"id":[{"id":"10.13039\/501100003807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.vaccine.2018.12.044","type":"journal-article","created":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T07:37:55Z","timestamp":1547883475000},"page":"1118-1125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Vaccination with recombinant adenoviruses expressing Toxoplasma gondii MIC3, ROP9, and SAG2 provide protective immunity against acute toxoplasmosis in mice"],"prefix":"10.1016","volume":"37","author":[{"given":"Dongchao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0356-7435","authenticated-orcid":false,"given":"Qijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2018.12.044_b0005","doi-asserted-by":"crossref","first-page":"eaaq0762","DOI":"10.1126\/sciadv.aaq0762","article-title":"Structures of monomeric and oligomeric forms of the Toxoplasma gondii perforin-like protein","volume":"4","author":"Ni","year":"2018","journal-title":"Sci Adv"},{"issue":"11","key":"10.1016\/j.vaccine.2018.12.044_b0010","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/nrmicro2858","article-title":"Modulation of innate immunity by Toxoplasma gondii virulence effectors","volume":"10","author":"Hunter","year":"2012","journal-title":"Nature Rev Microbiol"},{"key":"10.1016\/j.vaccine.2018.12.044_b0015","doi-asserted-by":"crossref","first-page":"39407","DOI":"10.1038\/srep39407","article-title":"Identification of a TNF-\u03b1 inducer MIC3 originating from the microneme of non-cystogenic, virulent Toxoplasma gondii","volume":"6","author":"Qiu","year":"2016","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.vaccine.2018.12.044_b0020","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1128\/IAI.00217-15","article-title":"Role of CD4+Foxp3+ regulatory T cells in protection induced by a live attenuated, replicating type I vaccine strain of Toxoplasma gondii","volume":"83","author":"Akbar","year":"2015","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2018.12.044_b0025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nri3598","article-title":"Innate immunity to Toxoplasma gondii infection","volume":"14","author":"Yarovinsky","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"87S","key":"10.1016\/j.vaccine.2018.12.044_b0030","article-title":"Evaluation of immunoprotection conferred by the subunit vaccines of GRA2 and GRA5 against acute toxoplasmosis in BALB\/c mice","volume":"7","author":"Ching","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2018.12.044_b0035","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3389\/fmicb.2018.00909","article-title":"Immune protection of rhoptry protein 21 (ROP21) of Toxoplasma gondii as a DNA vaccine against toxoplasmosis","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2018.12.044_b0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fcimb.2018.00163","article-title":"Chitosan microsphere used as an effective system to deliver a linked antigenic peptides vaccine protect mice against acute and chronic toxoplasmosis","volume":"8","author":"Guo","year":"2018","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"10.1016\/j.vaccine.2018.12.044_b0045","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1586\/erv.09.27","article-title":"Current status of toxoplasmosis vaccine development","volume":"8","author":"Kur","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"38","key":"10.1016\/j.vaccine.2018.12.044_b0050","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1016\/j.vaccine.2018.08.016","article-title":"Virus-like particle vaccines expressing Toxoplasma gondii rhoptry protein 18 and microneme protein 8 provide enhanced protection","volume":"36","author":"Lee","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.044_b0055","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.actatropica.2016.12.004","article-title":"Protective immune response in mice induced by a suicidal DNA vaccine encoding NTPase-II gene of Toxoplasma gondii","volume":"166","author":"Zheng","year":"2017","journal-title":"Acta Trop"},{"issue":"1","key":"10.1016\/j.vaccine.2018.12.044_b0060","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/JVI.01597-10","article-title":"Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors","volume":"85","author":"Rhee","year":"2011","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2018.12.044_b0065","doi-asserted-by":"crossref","first-page":"e63201","DOI":"10.1371\/journal.pone.0063201","article-title":"Recombinant vaccines against T. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1","volume":"8","author":"Mendes","year":"2013","journal-title":"PLoS ONE"},{"issue":"17","key":"10.1016\/j.vaccine.2018.12.044_b0070","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1016\/j.vaccine.2011.01.083","article-title":"Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine","volume":"29","author":"Miyata","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2018.12.044_b0075","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/infdis\/jir842","article-title":"Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis","volume":"205","author":"Maroof","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.12.044_b0080","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single centre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"389","author":"Zhu","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.12.044_b0085","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1051\/parasite\/2017013","article-title":"Vaccination with recombinant adenovirus expressing multi-stage antigens of Toxoplasma gondii by the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes","volume":"24","author":"Wang","year":"2017","journal-title":"Parasite"},{"key":"10.1016\/j.vaccine.2018.12.044_b0090","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.meegid.2016.10.006","article-title":"Recombinant canine adenovirus type-2 expressing TgROP16 provides partial protection against acute Toxoplasma gondii infection in mice","volume":"45","author":"Li","year":"2016","journal-title":"Infect Genet Evo"},{"key":"10.1016\/j.vaccine.2018.12.044_b0095","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12879-015-0815-1","article-title":"Protective efficacy of recombinant canine adenovirus type-2 expressing TgROP18 (CAV-2-ROP18) against acute and chronic Toxoplasma gondii infection in mice","volume":"15","author":"Li","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2018.12.044_b0100","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0092-8674(00)81071-5","article-title":"Toxoplasma invasion of mammalian cells is powered by the actin cytoskeleton of the parasite","volume":"84","author":"Dobrowolski","year":"1996","journal-title":"Cell"},{"issue":"5594","key":"10.1016\/j.vaccine.2018.12.044_b0105","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1126\/science.1074553","article-title":"Role of Toxoplasma gondii myosin A in powering parasite gliding and host cell invasion","volume":"298","author":"Meissner","year":"2002","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.vaccine.2018.12.044_b0110","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/emboj\/21.11.2526","article-title":"The Toxoplasma gondii protein MIC3 requires pro-peptide cleavage and dimerization to function as adhesin","volume":"21","author":"C\u00e9r\u00e8de","year":"2002","journal-title":"EMBO J"},{"issue":"1","key":"10.1016\/j.vaccine.2018.12.044_b0115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0166-6851(01)00397-8","article-title":"Characterization of TgROP9 (p36), a novel rhoptry protein of Toxoplasma gondii tachyzoites identified by T cell clone","volume":"119","author":"Reichmann","year":"2002","journal-title":"Mol Biochem Parasitol"},{"issue":"1","key":"10.1016\/j.vaccine.2018.12.044_b0120","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s13071-017-2387-y","article-title":"Screening and identification of host proteins interacting with Toxoplasma gondii SAG2 by yeast two-hybrid assay","volume":"10","author":"Lai","year":"2017","journal-title":"Parasit Vectors"},{"issue":"7","key":"10.1016\/j.vaccine.2018.12.044_b0125","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1007\/s00436-013-3425-0","article-title":"Evaluation of protective effect of multiantigenic DNA vaccine encoding MIC3 and ROP18 antigen segments of Toxoplasma gondii in mice","volume":"112","author":"Qu","year":"2013","journal-title":"Parasitol Res"},{"key":"10.1016\/j.vaccine.2018.12.044_b0130","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.exppara.2014.02.016","article-title":"Toxoplasma gondii: protective immunity induced by rhoptry protein 9 (TgROP9) against acute toxoplasmosis","volume":"139","author":"Chen","year":"2014","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.vaccine.2018.12.044_b0135","first-page":"1","article-title":"Sustained release of recombinant surface antigen 2 (rSAG2) from poly (lactide-co-glycolide) microparticles extends protective cell-mediated immunity against Toxoplasma gondii in mice","volume":"18","author":"Chuang","year":"2014","journal-title":"Parasitology"},{"key":"10.1016\/j.vaccine.2018.12.044_b0140","doi-asserted-by":"crossref","first-page":"11537","DOI":"10.1038\/ncomms11537","article-title":"The TatD-like DNase of Plasmodium is a virulence factor and a potential malaria vaccine candidate","volume":"7","author":"Chang","year":"2016","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.vaccine.2018.12.044_b0145","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/infdis\/jiy273","article-title":"Identification and immunological characterization of the ligand domain of Plasmodium vivax reticulocyte binding protein 1a","volume":"218","author":"Ntumngia","year":"2018","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2018.12.044_b0150","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/infdis\/jiw428","article-title":"T-cell immunoglobulin- and mucin-domain-containing molecule 3 signaling blockade Improves cell-mediated immunity against malaria","volume":"214","author":"Hou","year":"2016","journal-title":"J Infect Dis"},{"issue":"29","key":"10.1016\/j.vaccine.2018.12.044_b0155","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat7061","article-title":"Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8+ T cell dysfunction and maintain memory phenotype","volume":"3","author":"Wang","year":"2018","journal-title":"Sci Immunol"},{"issue":"538","key":"10.1016\/j.vaccine.2018.12.044_b0160","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aar3083","article-title":"The costimulatory molecule CD226 signals through VAV1 to amplify TCR signals and promote IL-17 production by CD4+ T cells","volume":"11","author":"Gaud","year":"2018","journal-title":"Sci Signal"},{"issue":"4","key":"10.1016\/j.vaccine.2018.12.044_b0165","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s12250-016-3756-y","article-title":"Virus like particle-based vaccines against emerging infectious disease viruses","volume":"31","author":"Liu","year":"2016","journal-title":"Virol Sin"},{"issue":"11","key":"10.1016\/j.vaccine.2018.12.044_b0170","doi-asserted-by":"crossref","DOI":"10.3390\/v10110631","article-title":"Recent advances in Zika virus vaccines","volume":"10","author":"Garg","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2018.12.044_b0175","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New vaccine technologies to combat outbreak situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2018.12.044_b0180","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr Gene Ther"},{"issue":"5","key":"10.1016\/j.vaccine.2018.12.044_b0185","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/cas.13228","article-title":"Recent advances in genetic modification of adenovirus vectors for cancer treatment","volume":"108","author":"Yamamoto","year":"2017","journal-title":"Cancer Sci"},{"issue":"7","key":"10.1016\/j.vaccine.2018.12.044_b0190","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.4049\/jimmunol.1501926","article-title":"A recombinant chimeric Ad5\/3 vector expressing a multistage Plasmodium antigen induces protective immunity in mice using heterologous prime-boost immunization regimens","volume":"197","author":"Cabrera-Mora","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.12.044_b0195","doi-asserted-by":"crossref","first-page":"31534","DOI":"10.1038\/srep31534","article-title":"Recombinant adenovirus of human p66Shc inhibits MCF-7 cell proliferation","volume":"6","author":"Yang","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2018.12.044_b0200","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/03079457.2017.1403009","article-title":"Development and evaluation of novel recombinant adenovirus-based vaccine candidates for infectious bronchitis virus and Mycoplasma gallisepticum in chickens","volume":"47","author":"Zhang","year":"2017","journal-title":"Avian Pathol"},{"issue":"4","key":"10.1016\/j.vaccine.2018.12.044_b0205","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/hum.2006.17.415","article-title":"Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of Toxoplasma gondii induces immune response and protection against infection in mice","volume":"17","author":"Caetano","year":"2006","journal-title":"Hum Gene Ther"},{"issue":"18","key":"10.1016\/j.vaccine.2018.12.044_b0210","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1016\/j.vaccine.2010.02.003","article-title":"Prime and boost immunization with influenza and adenovirus encoding the Toxoplasma gondii surface antigen 2 (SAG2) induces strong protective immunity","volume":"28","author":"Machado","year":"2010","journal-title":"Vaccine"},{"issue":"2\u20134","key":"10.1016\/j.vaccine.2018.12.044_b0215","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.vetpar.2011.04.039","article-title":"Immunogenicity and protective efficacy of two recombinant pseudorabies viruses expressing Toxoplasma gondii SAG1 and MIC3 proteins","volume":"181","author":"Nie","year":"2011","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.vaccine.2018.12.044_b0220","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.3389\/fmicb.2017.01733","article-title":"SAG4 DNA and peptide vaccination provides partial protection against T. gondii infection in BALB\/c mice","volume":"8","author":"Zhou","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2018.12.044_b0225","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fimmu.2017.00335","article-title":"CD103+CD8 T cells in the Toxoplasma-infected brain exhibit a tissue-resident memory transcriptional profile","volume":"8","author":"Landrith","year":"2017","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2018.12.044_b0230","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1086\/427660","article-title":"A combination of antigenic regions of Toxoplasma gondii microneme proteins induces protective immunity against oral infection with parasite cysts","volume":"191","author":"Beghetto","year":"2005","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2018.12.044_b0235","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.4049\/jimmunol.148.6.1792","article-title":"IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages","volume":"148","author":"Gazzinelli","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.12.044_b0240","first-page":"492","article-title":"Cerebral and ocular toxoplasmosis related with IFN-\u03b3, TNF-\u03b1, and IL-10 levels","volume":"5","author":"Meira","year":"2014","journal-title":"Front Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2018.12.044_b0245","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1365-3024.1998.00152.x","article-title":"A protective role for IL-6 during early infection with Toxoplasma gondii","volume":"20","author":"Jebbari","year":"1998","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2018.12.044_b0250","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fmicb.2017.00216","article-title":"Immuno-efficacy of a T. gondii secreted protein with an altered thrombospondin repeat (TgSPATR) as a novel DNA vaccine candidate against acute toxoplasmosis in BALB\/c mice","volume":"8","author":"Zheng","year":"2017","journal-title":"Front Microbiol"},{"issue":"9984","key":"10.1016\/j.vaccine.2018.12.044_b0255","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/S0140-6736(15)60553-0","article-title":"Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"385","author":"Zhu","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2018.12.044_b0260","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/infdis\/jiy187","article-title":"Immunization with a novel human type 5 adenovirus-vectored vaccine expressing the premembrane and envelope proteins of Zika virus provides consistent and sterilizing protection in multiple immunocompetent and immunocompromised animal models","volume":"218","author":"Guo","year":"2018","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2018.12.044_b0265","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2214-109X(16)30367-9","article-title":"Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"5","author":"Li","year":"2017","journal-title":"Lancet Glob Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18317298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18317298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:31:02Z","timestamp":1759401062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18317298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0264410X18317298"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.12.044","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination with recombinant adenoviruses expressing Toxoplasma gondii MIC3, ROP9, and SAG2 provide protective immunity against acute toxoplasmosis in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.12.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}